Financial Performance - Total assets increased to CNY 6,742,814,141.75, up from CNY 6,167,246,307.65, representing a growth of approximately 9.3% year-over-year[6] - Cash and cash equivalents at the end of the period reached CNY 1,609,820,536.78, compared to CNY 1,466,195,705.17, marking an increase of about 9.8%[12] - Net cash flow from operating activities was CNY 109,489,426.92, down from CNY 210,140,712.99, reflecting a decrease of approximately 48%[13] - Revenue from sales of goods and services received cash of CNY 886,042,330.28, a decline from CNY 957,849,360.44, indicating a decrease of about 7.5%[12] - Total liabilities increased to CNY 2,301,293,240.13, up from CNY 1,686,913,265.98, which is an increase of approximately 36.5%[6] - The company reported a profit distribution of -161,871,525.30[34] - The company reported a non-current asset disposal gain of ¥10,007,204.71[200] - Government subsidies recognized in the current period amounted to ¥7,677,596.17, closely related to the company's normal business operations[200] - The company experienced a loss of ¥65,558,104.56 from effective hedging activities not related to normal business operations[200] Cash Flow and Financing - The company reported a net cash outflow from investing activities of CNY -8,242,137.19, compared to CNY -672,379,825.43 in the previous period, showing a significant improvement[13] - Cash inflow from financing activities totaled CNY 1,334,157,300.00, compared to CNY 1,024,619,111.11, representing an increase of approximately 30.3%[13] - The company’s short-term borrowings rose to CNY 443,225,965.96 from CNY 197,210,132.90, reflecting an increase of about 125%[6] Inventory and Receivables - The company’s inventory decreased to CNY 23,441,799.95 from CNY 47,505,609.20, a reduction of approximately 50.7%[6] - The company’s other receivables increased significantly to CNY 1,401,789,909.48 from CNY 682,970,726.85, indicating a growth of about 105.5%[6] Financial Reporting and Compliance - The financial statements were approved for external release on August 28, 2023[38] - The company operates on a 12-month cycle for asset and liability liquidity classification[40] - The company has established a comprehensive financial reporting framework based on the parent company and its subsidiaries[42] - The board of directors and supervisors guarantee the accuracy and completeness of the semi-annual report, with no false records or misleading statements[188] - The financial report is signed and stamped by the legal representative and accounting personnel, ensuring compliance with regulatory requirements[180] Accounting Policies and Practices - The company recognizes financial assets and liabilities based on specific criteria, including fair value measurement and amortized cost[46] - The company has a policy for foreign currency business translation, with specific rates applied to various financial statement components[45] - The company has a structured approach to financial asset transfer recognition and measurement[48] - The company maintains a focus on ensuring accurate financial reporting in accordance with accounting standards[39] - The company has a defined method for handling financial liabilities, including those related to credit risk changes[46] - The company measures expected credit losses based on the risk of default weighted average of financial instruments[68] - The company uses a simplified measurement method to assess expected credit losses for receivables and contract assets[72] - The company applies a three-stage model to measure expected credit losses for financial instruments[57] - The company recognizes the difference between the carrying amount of transferred financial assets and the consideration received in current profits when derecognition conditions are met[64] - The company recognizes employee benefits as service costs and includes them in current profits or related asset costs[51] - The company assesses credit risk for financial instruments at each balance sheet date to determine if there has been a significant increase in credit risk since initial recognition[70] - The company recognizes short-term employee compensation as liabilities during the accounting period in which services are provided[66] - The company recognizes lease liabilities at the present value of unpaid lease payments, using the internal rate of return or incremental borrowing rate as the discount rate[35] - The estimated credit loss rates for accounts receivable are 5% for within 1 year, 30% for 1-2 years, 80% for 2-3 years, and 100% for over 3 years[85] - Long-term prepaid expenses are amortized over a period exceeding 1 year, with any unamortized balance recognized in the current period if the expenses do not benefit future periods[89] - Contract liabilities are recognized based on the relationship between the performance obligations and customer payments, with net amounts presented in the balance sheet[90] - The company accounts for employee benefits under defined contribution plans by recognizing the payable amount as a liability during the service period[92] - The company measures defined benefit plan obligations using actuarial assumptions and discounts them to present value, recognizing service costs and interest expenses in the current period[93] - The company recognizes contract costs directly related to obtaining contracts as assets, amortized based on the revenue recognition of related goods or services[98] - The initial investment cost for long-term equity investments is based on the book value of the acquired equity at the merger date, adjusted for any differences in capital reserves[100] - The company applies a perpetual inventory system for inventory management[96] - Inventory is measured at the lower of cost and net realizable value, with provisions for inventory write-downs made when costs exceed net realizable values[106] - The company capitalizes borrowing costs for qualifying assets during construction or production, but suspends capitalization if there is a significant interruption[121] - The company uses the straight-line method for depreciation of right-of-use assets, determining the period based on the lease term or the remaining useful life of the asset[123] - The company assesses whether investments are classified as joint control or significant influence based on decision-making power and control over financial and operational policies[124] - For long-term equity investments, the initial investment cost is determined based on the fair value of the consideration paid on the acquisition date[125] - The company recognizes impairment losses for contract-related assets when their carrying amount exceeds the expected recoverable amount[111] - The company applies the cost method for long-term equity investments in controlled entities and the equity method for joint ventures and associates[128] - The company recognizes gains or losses on the disposal of equity investments based on the difference between the consideration received and the carrying amount of the investment[129] Strategic Initiatives and Market Position - The company aims to be a trusted pharmaceutical enterprise in China, focusing on excellence in its operations[187] - The semi-annual report emphasizes the company's commitment to environmental and social responsibilities[191] - The company has not disclosed any new product launches or technological advancements in this report[191] - There is no mention of market expansion or mergers and acquisitions in the current report[191] - The company has confirmed that it meets the conditions for government subsidies, which will be recognized as deferred income[171] - The company primarily exports pharmaceutical products, with sales mainly denominated in USD, which exposes it to exchange rate fluctuations against RMB, impacting revenue and profitability[144] - The company is closely monitoring policy changes in the pharmaceutical industry, particularly related to centralized procurement, to mitigate operational risks[160] - The company will actively respond to international market changes and expand its domestic market presence to stabilize its international market position[144] - The company has implemented measures to hedge against exchange rate risks, including the use of currency derivatives[144] - The company has established a pricing adjustment mechanism in contracts to protect against significant exchange rate fluctuations[144] Shareholding and Dividends - The company reported a total shareholding of 642,782,587 shares held by the actual controller, Mr. Wang Yunfu, representing 73.20% of Donggang Industrial Group[185] - The company plans not to distribute cash dividends, issue bonus shares, or increase capital from reserves[189]

单位：人民币万元 浙江海翔药业股份有限公司 2023年半年度非经营性资金占用及其他关联资金往来 情况汇总表 | 非经 | 营性 | 资金 | 占用 | | | | | 占用 | 资金 | | 方名 称 | 占用 方与 关联 | 上市 公司 关系 | 的 上市 | 公司 核算 的 会计 科目 | 20 23年 期初 金余 额 | 占用 资 2023 计发 | 年半 年度 资金 生额 （不含 | 占用 累 利息 ） | 2023 年半 年度 占 用资 金的 利息 （如 有） | 20 23年 半年 度偿 计发 生金 额 | 还累 2023 年半 资金 | 年度 期末 占用 余额 | 占用 形成 原因 | | 占用 性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 控股 股东 、实 | 际控 | 制人 及其 ● | | 附属 企 ...

证券代码：002099 证券简称：海翔药业 公告编号：2023-043 浙江海翔药业股份有限公司 第七届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 浙江海翔药业股份有限公司（以下简称"公司"）第七届监事会第三次会议 于 2023 年 8 月 18 日以电子邮件形式发出通知，于 2023 年 8 月 28 日以现场方 式在公司会议室召开，会议应出席监事 3 人，实际出席监事 3 人，公司部分董 事、高级管理人员列席会议。会议召开符合《公司法》及《公司章程》的规定， 合法有效。会议由监事会主席陈敏杰先生主持，经过与会监事的充分讨论，会议 审议通过了如下议案： 一、审议通过了《2023 年半年度报告及摘要》 监事会认为董事会编制和审核公司《2023 年半年度报告》的程序符合法 律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司 的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 《2023 年半年度报告全文》及《2023 年半年度报告摘要》（公告编号： 2023-044）于 2023 年 8 月 30 日刊登在巨 ...

证券代码：002099 证券简称：海翔药业 公告编号：2023-047 浙江海翔药业股份有限公司 关于为合并报表范围内子公司提供担保的进展公告 2023 年 2 月 3 日，公司与汇丰银行（中国）有限公司签署《保证书》，同 意为香港港翔开展各类银行业务提供 1,650 万元美金连带责任担保，具体详见 公司于 2023 年 2 月 4 日在《证券时报》、《上海证券报》和巨潮资讯网 （www.cninfo.com.cn）上披露的《关于为合并报表范围内子公司提供担保的进 展公告》（公告编号：2023-005）。 二、担保进展情况 2023 年 8 月 28 日，公司与汇丰银行（中国）有限公司重新签署新《保证 书》，同意公司继续为香港港翔开展各类银行业务提供 1,650 万元美金连带责 任担保。原《保证书》于新《保证书》签署之日起失效。本次对外担保系原担 保到期后展期，未新增担保额度。 三、保证书的主要内容 1、担保金额：1,650 万元美金。 2、担保方式：连带责任担保。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、担保情况概述 浙江海翔药业股份有限公司（以 ...

浙江海翔药业股份有限公司 股票代码：002099 股票简称：海翔药业 公告编号：2023-046 欢迎广大投资者积极参与。 特此公告。 浙江海翔药业股份有限公司 董 事 会 二零二三年八月三十日 关于举行 2023 年半年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江海翔药业股份有限公司（以下简称"公司"）于 2023 年 8 月 30 日披露 了 2023 年半年度报告。为了让广大投资者能进一步了解公司 2023 年半年度的经 营情况，公司将于 2023 年 9 月 6 日下午 15:00 至 17:00 在深圳证券交易所互动 易平台举办 2023 年半年度业绩说明会，与投资者进行沟通交流，听取投资者的 意见和建议。本次业绩说明会将采用网络远程方式举行，投资者可登录深圳证券 交易所互动易平台（http://irm.cninfo.com.cn）进入"云访谈"栏目参与本次 业绩说明会。 公司出席本次业绩说明会的人员有：公司总经理许国睿、董事会秘书兼财务 总监王晓洋、独立董事俞永平。（如有特殊情况，参与人员会有调整） 为充分尊重投资者 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江海翔药业股份有限公司（以下简称"公司"）第七届董事会第五次会 议于 2023 年 8 月 18 日以电子邮件形式发出通知，于 2023 年 8 月 28 日以现场 加视频方式在公司会议室召开，会议应出席董事 8 人，实际出席董事 8 人，其 中，王扬超先生、姚冰先生、陶红女士、王晓洋女士出席现场会议，许国睿先 生、俞永平先生、钱建民先生、梁超女士以视频方式参会，公司监事、高级管 理人员列席会议。会议召开符合《公司法》及《公司章程》的规定，合法有 效。会议由董事长王扬超先生主持，经过与会董事的充分讨论，会议审议通过 了如下议案： 一、审议通过了《2023 年半年度报告及摘要》 表决结果：同意票 8 票，反对票 0 票，弃权票 0 票。 《2023 年半年度报告全文》及《2023 年半年度报告摘要》（公告编号： 2023-044）于 2023 年 8 月 30 日刊登在巨潮资讯网，《2023 年半年度报告摘 要》同时刊登于《证券时报》、《证券日报》、《上海证券报》。 二、审议通过了《2023 年半年度募集资金存放 ...

根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募 集资金管理和使用的监管要求》和深圳证券交易所印发的《深圳证券交易所上 市公司自律监管指引第 1 号——主板上市公司规范运作》的规定，将本公司募 集资金 2023 年半年度存放与使用情况专项说明如下。 一、募集资金基本情况 证券代码：002099 证券简称：海翔药业 公告编号：2023-045 浙江海翔药业股份有限公司 2023 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 （一）实际募集资金金额和资金到账时间 经中国证券监督管理委员会证监许可〔2016〕765 号文核准，并经深圳证券 交易所同意，本公司由主承销商国泰君安证券股份有限公司采用非公开发行方 式，向特定对象非公开发行人民币普通股(A 股)股票 99,890,023 股，发行价为 每股人民币 10.28 元，共计募集资金 1,026,869,436.44 元，坐扣承销费和保荐 费等 10,000,000.00 元(含税)后的募集资金为 1,016,869,436.44 元，已由主承 销商国 ...

3、截至 2023 年 6 月 30 日，公司除对合并报表范围内子公司担保外，不存 在为控股股东及其他关联方提供担保的情况，未有逾期对外担保。公司对外担 保均符合（证监会公告〔2022〕26 号）以及《公司章程》的规定，履行了必要 的审议和决策程序，信息披露充分完整。 （本页无正文，为《浙江海翔药业股份有限公司独立董事关于第七届董事会第 五次会议相关事项的独立意见》之签字页） 浙江海翔药业股份有限公司 独立董事关于第七届董事会第五次会议相关事项的独立意见 根据中国证监会《上市公司独立董事管理办法》、《深圳证券交易所股票 上市规则》、《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公 司规范运作》和《公司章程》等有关规定，作为公司独立董事，在审阅有关文 件及尽职调查后，基于独立判断的立场，对公司第七届董事会第五次会议相关 事项发表意见如下： 一、关于公司关联方资金占用和对外担保情况的专项说明和独立意见 根据《上市公司监管指引第 8 号——上市公司资金往来、对外担保的监管 要求》（证监会公告〔2022〕26 号）等相关规定的要求，作为公司的独立董 事，基于独立判断立场，为了维护公司及股东特别是中小股东的 ...

Financial Performance - The company's operating revenue for the current period is ¥634,047,833.60, a decrease of 21.19% compared to the same period last year[20]. - Total operating revenue for the current period is $634.05 million, down 21.14% from $804.53 million in the previous period[33]. - Net profit attributable to shareholders for the current period is ¥42,101,946.61, down 51.62% year-over-year[20]. - Net profit for the current period is $41.85 million, a decrease of 51.66% compared to $86.55 million in the previous period[34]. - Basic and diluted earnings per share are both ¥0.02, down 60.00% from ¥0.05 in the previous year[20]. - The net profit after deducting non-recurring gains and losses is -¥3,289,938.74, representing a decline of 104.29% compared to the previous year[20]. Cash Flow - Net cash flow from operating activities was CNY 159,451,304.75, a slight increase from CNY 149,627,750.29, reflecting a growth of approximately 5.5%[14]. - Cash flow from financing activities generated a net inflow of CNY 603,707,509.29, compared to a net outflow of CNY -4,572,083.35 in the previous period[15]. - The company reported a net cash inflow from investing activities of CNY 81,685,962.84, a significant recovery from a net outflow of CNY -118,848,272.85 in the previous period[14]. - Net cash flow from investing activities improved by 168.73% to 81,685,962.84 from -118,848,272.85 mainly due to the recovery of investments and dividends[46]. - Net cash flow from financing activities increased significantly by 13,304.21% to 603,707,509.29 from -4,572,083.35 due to increased bank borrowings[46]. Assets and Liabilities - Total liabilities increased to CNY 2,912,033,729.61, up from CNY 2,288,184,973.02, representing a growth of approximately 27.2% year-over-year[10]. - The company’s total assets reached CNY 9,058,797,473.33, up from CNY 8,393,099,770.24, representing an increase of approximately 7.9%[10]. - Current assets totaled 4,027,776,667.20, up from 3,245,690,461.75, indicating a significant increase in liquidity[50]. - Cash and cash equivalents increased to 2,305,531,103.61 from 1,490,815,956.57, reflecting improved cash management[50]. - Total assets rose to 9,058,797,473.33 from 8,393,099,770.24, indicating growth in the company's asset base[50]. - Non-current assets decreased to 5,031,020,806.13 from 5,147,409,308.49, showing a reduction in long-term investments[50]. Shareholder Information - The company reported a total of 32,095 common shareholders at the end of the reporting period[27]. - The largest shareholder, Zhejiang Donggang Industrial Co., Ltd., holds 32.37% of the shares, totaling 523,982,587 shares[27]. - Shareholders' equity attributable to the parent company is ¥6,150,080,587.84, a slight increase of 0.24% compared to the previous year[20]. Operating Costs and Expenses - Total operating costs decreased to $642.13 million, a reduction of 9.25% from $708.00 million in the previous period[33]. - Financial expenses increased significantly to $24.96 million, up 547.97% from $3.85 million in the previous period, primarily due to exchange losses from the depreciation of the US dollar[44]. - Operating expenses increased by 96.56% to 245,032.99 from 124,663.16 primarily due to an increase in fixed asset scrapping[46]. - Income tax expenses decreased by 84.46% to 2,221,604.16 from 14,293,732.25 due to a reduction in total profit[46]. Foreign Exchange and Other Income - The company experienced significant foreign exchange losses due to large fluctuations in exchange rates during the reporting period[41]. - Non-operating income includes government subsidies of ¥3,564,265.41 and gains from the disposal of non-current assets of ¥8,248,695.14[21]. - Investment income rose to $20.09 million, an increase of 244.93% from $5.82 million in the previous period, mainly due to received dividends[44]. - The company reported a significant increase in asset disposal gains to $8.30 million, up 5023.79% from $162,040.17 in the previous period[44].